These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 28673201)

  • 21. Minimal interference: A basis for selecting ART for prevention with positives.
    Lebouché B; Engler K; Lévy JJ; Gilmore N; Spire B; Rozenbaum W; Routy JP
    AIDS Care; 2013; 25(10):1284-90. PubMed ID: 23394079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.
    Ogbuagu O; Bruce RD
    Curr HIV/AIDS Rep; 2014 Dec; 11(4):505-12. PubMed ID: 25342571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget impact analysis of HIV testing in the VA healthcare system.
    Anaya HD; Chan K; Karmarkar U; Asch SM; Bidwell Goetz M
    Value Health; 2012 Dec; 15(8):1022-8. PubMed ID: 23244803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study.
    Fowler N; Arkell P; Abouyannis M; James C; Roberts L
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19563. PubMed ID: 25394070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
    Gopalappa C; Stover J; Shaffer N; Mahy M
    AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.
    Libois A; Florence E; Derdelinckx I; Yombi JC; Henrard S; Uurlings F; Vandecasteele S; Allard SD; Demeester R; Van Wanzeele F; Ausselet N; De Wit S
    Acta Clin Belg; 2018 Aug; 73(4):275-280. PubMed ID: 29429390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.
    Schneider K; Gray RT; Wilson DP
    Clin Infect Dis; 2014 Apr; 58(7):1027-34. PubMed ID: 24385445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aligning budget with U.S. National HIV prevention priorities.
    Valdiserri RO; Ogden LO; Janssen RS; Onorato I; Martin T
    J Public Health Manag Pract; 2004; 10(2):140-7. PubMed ID: 14967981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention.
    Bailey TC; Sugarman J
    Curr HIV Res; 2013 Sep; 11(6):473-80. PubMed ID: 24033297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating zero transmission of HIV in the MSM population: a UK modelling case study.
    Massey K; Vardanega V; Chaponda M; Eddowes LA; Hearmon N
    Arch Public Health; 2023 Nov; 81(1):201. PubMed ID: 37986184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care.
    Van Beckhoven D; Serrien B; Montourcy M; Verhofstede C; Van den Bossche D; Libois A; De Geyter D; Martin T; Van den Eynde S; Vuylsteke B; Darcis G; van Halem K; Florence E; Deblonde J;
    BMC Infect Dis; 2022 Dec; 22(1):901. PubMed ID: 36463126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frontloading HIV financing maximizes the achievable impact of HIV prevention.
    Anderson SJ; Ghys PD; Ombam R; Hallett TB
    J Int AIDS Soc; 2018 Mar; 21(3):e25087. PubMed ID: 29498234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.
    Duwal S; Winkelmann S; Schütte C; von Kleist M
    PLoS Comput Biol; 2015 Apr; 11(4):e1004200. PubMed ID: 25927964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.
    Demeulemeester R; Savy N; Mounié M; Molinier L; Delpierre C; Dellamonica P; Allavena C; Pugliesse P; Cuzin L; Saint-Pierre P; Costa N
    BMC Health Serv Res; 2022 Apr; 22(1):567. PubMed ID: 35477443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Numerical optimal control for HIV prevention with dynamic budget allocation.
    Gromov D; Bulla I; Silvia Serea O; Romero-Severson EO
    Math Med Biol; 2018 Dec; 35(4):469-491. PubMed ID: 29106566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does prevention pay?
    Meltzer D
    Med Care; 2015 Apr; 53(4):291-2. PubMed ID: 25769054
    [No Abstract]   [Full Text] [Related]  

  • 38. Global Efforts against HIV Epidemic and HIV Vaccine Development.
    Tanuma J
    Trop Med Health; 2014 Jun; 42(2 Suppl):91-2. PubMed ID: 25425957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving estimated health and budget gains through combined HIV prevention: theoretical results require real-world effort.
    Vermeersch S; Callens S; De Wit S; Goffard JC; Van Beckhoven D; Annemans L
    Acta Clin Belg; 2018 Apr; 73(2):167. PubMed ID: 29560819
    [No Abstract]   [Full Text] [Related]  

  • 40. The aspirational necessity of HIV prevention.
    Corey L; Gray GE; Buchbinder SP
    J Int AIDS Soc; 2019 May; 22(5):e25289. PubMed ID: 31099956
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.